PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Atorvastatin - Lipid modification
PAD Profile : Atorvastatin - Lipid modification
Keywords :
Statins, primary hypercholesterolaemia, mixed hyperlipidaemia, familial hypercholesterolaemia, high cholesterol, raised cholesterol, lipid lowering, lipid-lowering
Brand Names Include :
Lipitor
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC atorvastatin has been considered by the PCN and has been assigned a GREEN traffic light status.
NOTE - the branded product, Lipitor, was considered BLACK at the PCN in May 2017.
03 September 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
NICE published CG 181 in July 2014 to update and replace NICE CG 67 and NICE TA 94 (statins for the prevention of cardiovascular events).
This latest guidance replaces all former Surrey guidance for lipid modification - see NICE CG 181 below.
If statin therapy is considered appropriate the guidelines recommend using atorvastin 20mg for primary prevention and atorvastatin 80mg for secondary prevention.
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs